CJC-1295 (No DAC) — 10mg
Research-grade CJC-1295 (No DAC), a synthetic 30-amino-acid GHRH analog also known as Modified GRF (1-29). Studied for short-acting growth hormone-releasing hormone receptor activation and pulsatile GH secretion patterns. 10mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It contains four strategic amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that enhance enzymatic stability over native GHRH (1-29) / Sermorelin while retaining a short half-life of approximately 30 minutes. This pulsatile profile distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), which has an extended ~6-8 day half-life via albumin binding. The "No DAC" variant is widely used in research models examining short-acting GHRH analog activity, frequently paired with Ipamorelin for combined GHRH/GHS pathway research.
BENEFITS
GHRH receptor binding — studied as a stabilized GHRH analog with enhanced enzymatic resistance
Pulsatile profile — short half-life (~30 min) preserves natural GH release patterns
Stack compatibility — commonly paired with Ipamorelin in dual-pathway GH research
Modified GRF identity — well-documented in published GHRH literature
Research convenience — single 10mg vial for extended research protocols
WHAT RESEARCHERS LOOK AT
Pulsatile growth hormone release in pituitary cell models
IGF-1 secretion patterns following GHRH analog administration
Comparative half-life studies vs. native GHRH (1-29) and CJC-1295 (DAC)
Synergy with ghrelin receptor agonists like Ipamorelin
Bone density and longitudinal growth research models